Research ExplorerPublicationsMyosin II Reactivation and Cytoskeletal Remodeling as a Hall...

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance

Standard

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. / Orgaz, Jose L; Crosas-Molist, Eva; Sadok, Amine; Perdrix-Rosell, Anna; Maiques, Oscar; Rodriguez-Hernandez, Irene; Monger, Jo; Mele, Silvia; Georgouli, Mirella; Bridgeman, Victoria; Karagiannis, Panagiotis; Lee, Rebecca; Pandya, Pahini; Boehme, Lena; Wallberg, Fredrik; Tape, Chris; Karagiannis, Sophia N; Malanchi, Ilaria; Sanz-Moreno, Victoria.

In: CANCER CELL, Vol. 37, No. 1, 13.01.2020, p. 85-103.e9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Orgaz, JL, Crosas-Molist, E, Sadok, A, Perdrix-Rosell, A, Maiques, O, Rodriguez-Hernandez, I, Monger, J, Mele, S, Georgouli, M, Bridgeman, V, Karagiannis, P, Lee, R, Pandya, P, Boehme, L, Wallberg, F, Tape, C, Karagiannis, SN, Malanchi, I & Sanz-Moreno, V 2020, 'Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance', CANCER CELL, vol. 37, no. 1, pp. 85-103.e9. https://doi.org/10.1016/j.ccell.2019.12.003

APA

Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., Karagiannis, P., Lee, R., Pandya, P., Boehme, L., Wallberg, F., Tape, C., Karagiannis, S. N., Malanchi, I., & Sanz-Moreno, V. (2020). Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. CANCER CELL, 37(1), 85-103.e9. https://doi.org/10.1016/j.ccell.2019.12.003

Vancouver

Orgaz JL, Crosas-Molist E, Sadok A, Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I et al. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. CANCER CELL. 2020 Jan 13;37(1):85-103.e9. https://doi.org/10.1016/j.ccell.2019.12.003

Bibtex

@article{fbbb0e74b56f46b59f978ac5d81739f8,
title = "Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance",
abstract = "Despite substantial clinical benefit of targeted and immune checkpoint blockade-based therapies in melanoma, resistance inevitably develops. We show cytoskeletal remodeling and changes in expression and activity of ROCK-myosin II pathway during acquisition of resistance to MAPK inhibitors. MAPK regulates myosin II activity, but after initial therapy response, drug-resistant clones restore myosin II activity to increase survival. High ROCK-myosin II activity correlates with aggressiveness, identifying targeted therapy- and immunotherapy-resistant melanomas. Survival of resistant cells is myosin II dependent, regardless of the therapy. ROCK-myosin II ablation specifically kills resistant cells via intrinsic lethal reactive oxygen species and unresolved DNA damage and limits extrinsic myeloid and lymphoid immunosuppression. Efficacy of targeted therapies and immunotherapies can be improved by combination with ROCK inhibitors.",
author = "Orgaz, {Jose L} and Eva Crosas-Molist and Amine Sadok and Anna Perdrix-Rosell and Oscar Maiques and Irene Rodriguez-Hernandez and Jo Monger and Silvia Mele and Mirella Georgouli and Victoria Bridgeman and Panagiotis Karagiannis and Rebecca Lee and Pahini Pandya and Lena Boehme and Fredrik Wallberg and Chris Tape and Karagiannis, {Sophia N} and Ilaria Malanchi and Victoria Sanz-Moreno",
note = "Copyright {\textcopyright} 2019 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = jan,
day = "13",
doi = "10.1016/j.ccell.2019.12.003",
language = "English",
volume = "37",
pages = "85--103.e9",
journal = "CANCER CELL",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

RIS

TY - JOUR

T1 - Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance

AU - Orgaz, Jose L

AU - Crosas-Molist, Eva

AU - Sadok, Amine

AU - Perdrix-Rosell, Anna

AU - Maiques, Oscar

AU - Rodriguez-Hernandez, Irene

AU - Monger, Jo

AU - Mele, Silvia

AU - Georgouli, Mirella

AU - Bridgeman, Victoria

AU - Karagiannis, Panagiotis

AU - Lee, Rebecca

AU - Pandya, Pahini

AU - Boehme, Lena

AU - Wallberg, Fredrik

AU - Tape, Chris

AU - Karagiannis, Sophia N

AU - Malanchi, Ilaria

AU - Sanz-Moreno, Victoria

N1 - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2020/1/13

Y1 - 2020/1/13

N2 - Despite substantial clinical benefit of targeted and immune checkpoint blockade-based therapies in melanoma, resistance inevitably develops. We show cytoskeletal remodeling and changes in expression and activity of ROCK-myosin II pathway during acquisition of resistance to MAPK inhibitors. MAPK regulates myosin II activity, but after initial therapy response, drug-resistant clones restore myosin II activity to increase survival. High ROCK-myosin II activity correlates with aggressiveness, identifying targeted therapy- and immunotherapy-resistant melanomas. Survival of resistant cells is myosin II dependent, regardless of the therapy. ROCK-myosin II ablation specifically kills resistant cells via intrinsic lethal reactive oxygen species and unresolved DNA damage and limits extrinsic myeloid and lymphoid immunosuppression. Efficacy of targeted therapies and immunotherapies can be improved by combination with ROCK inhibitors.

AB - Despite substantial clinical benefit of targeted and immune checkpoint blockade-based therapies in melanoma, resistance inevitably develops. We show cytoskeletal remodeling and changes in expression and activity of ROCK-myosin II pathway during acquisition of resistance to MAPK inhibitors. MAPK regulates myosin II activity, but after initial therapy response, drug-resistant clones restore myosin II activity to increase survival. High ROCK-myosin II activity correlates with aggressiveness, identifying targeted therapy- and immunotherapy-resistant melanomas. Survival of resistant cells is myosin II dependent, regardless of the therapy. ROCK-myosin II ablation specifically kills resistant cells via intrinsic lethal reactive oxygen species and unresolved DNA damage and limits extrinsic myeloid and lymphoid immunosuppression. Efficacy of targeted therapies and immunotherapies can be improved by combination with ROCK inhibitors.

U2 - 10.1016/j.ccell.2019.12.003

DO - 10.1016/j.ccell.2019.12.003

M3 - SCORING: Journal article

C2 - 31935375

VL - 37

SP - 85-103.e9

JO - CANCER CELL

JF - CANCER CELL

SN - 1535-6108

IS - 1

ER -